IOL Chemicals & Pharmaceuticals Ltd
IOL Chemicals & Pharmaceuticals Q2 Results 2026 (FY27): Revenue ₹795.0 Cr, PAT ₹65.0 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #72 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
IOL Chemicals & Pharmaceuticals Ltd Q2 FY27 key numbers
- Revenue
- Q2 FY27 EBITDA: ₹114.9 Cr (14.4% margin), up 79.6% YoY.
As stated in IOL Chemicals & Pharmaceuticals Ltd's Q2 FY27 investor presentation · published 30 Oct 2026. Reported figures, not investment advice.
Based on IOL Chemicals & Pharmaceuticals Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Q2 FY27 Financials: - EBITDA: ₹114.9 Cr, up 79.6% YoY - EBITDA Margin: 14.4% - Profit after Tax (PAT): ₹65.0 Cr, up 116.8% YoY - PAT Margin: 8.1% - Margin Outlook (FY26–27 Guidance):
From IOL Chemicals & Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 31 Oct 2026.
Revenue & Sales Performance
- Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7).
- H1 FY27 revenue from operations: ₹1,551.3 Cr, a 38.6% YoY increase from ₹1,119.2 Cr in H1 FY26 (Page 5).
- Q2 FY27 EBITDA: ₹114.9 Cr (14.4% margin), up 79.6% YoY (Page 7).
- Q2 FY27 PAT: ₹65.0 Cr, up 116.8% YoY with an 8.1% PAT margin (Page 7).
2 more points from IOL Chemicals & Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what IOL Chemicals & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Pharmaceutical Formulations CDMO Facility
- Investment: ₹110 Cr
- Capacity: 1,500 million tablets annually
- Status: Newly installed, FY27 commissioning
- Focus: Serving European customers, forward integration
- Specialty Chemicals Facility (Long-term Tolling Agreement)
- Investment: ₹35 Cr
- Status: Dedicated facility commissioning in FY27
- Funded through internal accruals
- Ibuprofen Capacity Expansion at Barnala
- Investment: ₹350 Cr
- Capacity added: 6,000 MTPA, total 18,000 MTPA
- Status: Backward integration; commissioning in FY28
- General Capex Guidance for FY26–27
2 more points from IOL Chemicals & Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what IOL Chemicals & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what IOL Chemicals & Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
IOL Chemicals & Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹795 Cr, net profit ₹65 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What IOL Chemicals's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
- Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
- Lyka Labs Ltd (Q2 FY27)
Year-on-Year revenue growth for the quarter: approximately 104.5% increase (8,650.89 vs 4,230.94 lakhs). Key results statement takeaways from Lyka Labs Ltd's Q2
- Anuh Pharma Ltd (Q2 FY27)
64.13 lakhs (~0.34% decline). Key results statement takeaways from Anuh Pharma Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
IOL Chemicals & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were IOL Chemicals & Pharmaceuticals Ltd Q2 FY27 results?
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Q2 FY27 Financials: - EBITDA: ₹114.9 Cr, up 79.6% YoY - EBITDA Margin: 14.4% - Profit after Tax (PAT): ₹65.0 Cr, up 116.8% YoY - PAT Margin: 8.1% - Margin Outlook (FY26–27 Guidance):
What is IOL Chemicals & Pharmaceuticals Ltd share price analysis?
IOL Chemicals & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 29.5 with a market cap of ₹5,214 Cr. Investors should review the full earnings analysis for detailed insights.
Is IOL Chemicals & Pharmaceuticals Ltd planning capital expenditure?
Pharmaceutical Formulations CDMO Facility - Investment: ₹110 Cr - Capacity: 1,500 million tablets annually - Status: Newly installed, FY27 commissioning - Focus: Serving European cus
Keep IOL Chemicals & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.